Chemomab Therapeutics News

Maxim Group Initiates Coverage On Chemomab Therapeutics With Buy Rating, Announces Price Target of $4

Maxim Group analyst Michael Okunewitch initiates coverage on Chemomab Therapeutics with a Buy rating and announces Price Target of $4.

Analyst UpgradesMay 13 11:32

Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy?

Yahoo FinanceMay 10 08:55

Analysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)

TipRanksMay 10 07:30

Chemomab Therapeutics Shares Are Trading Higher After the Company Reported a Year-over-year Increase in Q1 GAAP EPS Results.

Chemomab Therapeutics Shares Are Trading Higher After the Company Reported a Year-over-year Increase in Q1 GAAP EPS Results.

BenzingaMay 9 11:47

Chemomab Therapeutics (CMMB.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -0.28 dollars, previous value of -0.80 dollars.

Chemomab Therapeutics (CMMB.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -0.28 dollars, previous value of -0.80 dollars.

Zhitong FinanceMay 9 06:16

Chemomab Therapeutics Q1 2024 GAAP EPS $(0.28) Up From $(0.80) YoY

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.28) per share. This is a 65 percent increase over losses of $(0.80) per share from the same period last year.

BenzingaMay 9 06:10

Chemomab Therapeutics 1Q EPS 1.4c >CMMB

Chemomab Therapeutics 1Q EPS 1.4c >CMMB

Dow JonesMay 9 06:07

Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Futu NewsMay 9 06:02 · Announcements

Chemomab Therapeutics Receives Nasdaq Extension

TipRanksMay 8 06:58

12 Health Care Stocks Moving In Monday's Intraday Session

GainersNRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 39.5% to $2.93 during Monday's regular session. The company's market cap stands at $30.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stoc

BenzingaMay 6 11:31

Chemomab Therapeutics Price Target Announced at $6.00/Share by Oppenheimer

Chemomab Therapeutics Price Target Announced at $6.00/Share by Oppenheimer

Dow JonesMay 6 07:02

Analysts Offer Insights on Healthcare Companies: Andlauer Healthcare Group (OtherANDHF), ACADIA Pharmaceuticals (ACAD) and Chemomab Therapeutics (CMMB)

TipRanksMay 6 06:50

Oppenheimer Upgrades Chemomab Therapeutics to Outperform

Oppenheimer Upgrades Chemomab Therapeutics to Outperform.

MT NewswiresMay 6 06:06

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

TEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammat

GlobeNewswireMay 2 06:00

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with

GlobeNewswireApr 24 06:00

Chemomab Reports New Peer-Reviewed Publication Reinforcing The Clinical Association Of Its CCL24 Target With Disease Severity and Mortality In Systemic Sclerosis

Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic Sclerosis (SSc), Showing that It is Associated with Disease Severity Across the Fibrotic a

BenzingaApr 18 06:11

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

—"Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis" Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving Views on Clinical Development—

GlobeNewswireApr 2 06:00

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) today reported that the European Patent Office has granted a new patent for CM-101, Chemomab's first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive fibrosis and inflammation.

GlobeNewswireMar 25 06:06

Oppenheimer Maintains Perform on Chemomab Therapeuticsto Perform

Oppenheimer analyst Jeff Jones maintains Chemomab Therapeutics from Perform to Perform.

Analyst UpgradesMar 8 07:45

Chemomab Therapeutics Q4 EPS $(0.26) Up From $(0.72) YoY

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.26) per share. This is a 63.89 percent increase over losses of $(0.72) per share from the same period last year.

BenzingaMar 7 06:06